- September 3, 2026
- Category: Press release
Cachan, France | Thursday, 3rd September, 2026
DOSIsoft Theranostics, the DOSIsoft entity dedicated to advancing personalized Radiopharmaceutical Therapy (RPT) through innovative patient-specific dosimetry software, today announced its participation in the Foundation for the National Institutes of Health (FNIH) Precision Dosimetry Imaging Biomarker (PDIB) Project. This international initiative aims to advance radiopharmaceutical therapy (RPT) through improved dosimetry, supporting more effective and personalized cancer treatments.
The three-year, $7.1 million PDIB Project brings together leading experts from government agencies, academia, medical societies, patient advocacy organizations, and industry. The initiative aims to establish standardized imaging protocols and reliable absorbed dose measurements, providing a common framework for more consistent and personalized treatment strategies in RPT. The PDIB Project is led by the FNIH, with Professor John Sunderland and Professor Stephen Graves of the University of Iowa serving as Principal Investigators.
“We are proud to join the PDIB Project, a landmark initiative that will help shape the future of personalized radiopharmaceutical therapy,” said Marc Uszynski, CEO, DOSIsoft. “The future of theranostics depends on robust, standardized dosimetry practices built on strong scientific collaboration. We are honored to contribute to an initiative that brings together leading organizations committed to advancing precision medicine and improving patient care.”
DOSIsoft Theranostics’ participation in the PDIB Project reinforces its commitment to driving innovation in personalized dosimetry and Molecular Radiotherapy through international scientific collaboration.
About PLANET
PLANET is a next-generation platform for personalized voxel-based dosimetry in Radiopharmaceutical Therapy (RPT) and Selective Internal Radiation Therapy (SIRT), designed to support patient-specific dosimetric assessment and clinical decision-making. PLANET is a Class IIb CE-marked medical device under MDR (EU) 2017/745 and FDA 510(k) cleared.
About DOSIsoft
Founded in 2002, DOSIsoft is a market leader in dosimetry software for radiation oncology and nuclear medicine, dedicated to improving cancer treatment quality and patient safety. With more than 1,000 installations across 800+ hospital centers in 80 countries. A spin-off from Gustave Roussy and Institut Curie, DOSIsoft continues to innovate through close collaboration with leading cancer centers worldwide. Building on its long-standing expertise in dose calculation and treatment planning, DOSIsoft established DOSIsoft Theranostics as a dedicated entity to further advance personalized Molecular Radiotherapy and theranostics worldwide. www.dosisoft.com
About the FNIH Biomarkers Consortium
Established by Congress in 1990 to support the mission of the National Institutes of Health (NIH), the Foundation for the NIH (FNIH) builds public-private partnerships connecting leading biomedical scientists at the NIH, life sciences companies, foundations, academia, and regulatory agencies. The FNIH Biomarkers Consortium leads cross-sector efforts to advance biomarkers and accelerate the development of new therapeutics and health technologies. For more information about the FNIH Biomarkers Consortium and the PDIB Project, please visit www.fnih.org/our-programs/biomarkers-consortium
Press contact Xiaolu CHEN | xiaolu.chen@dosisoft.com
DOSIsoft +33 (0)1 41 24 26 26 | 45/47, Avenue Carnot, 94230 Cachan, France
DOSIsoft Inc. +1 (844) 772-3674 | 121 Alhambra Plaza # 1000, Coral Gables, FL 33134, USA